What is the recommended use and dosage of UBRELVY (Ubrogepant) for treating migraine attacks in adults?

From the Guidelines

Ubrelvy (ubrogepant) is suggested for the short-term treatment of migraine, as indicated by the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline for the management of headache 1. The recommended dosage of Ubrelvy for treating migraine attacks in adults is 50 mg or 100 mg taken orally as a single dose at the onset of migraine symptoms. Some key points to consider when prescribing Ubrelvy include:

• If needed, a second dose may be taken at least 2 hours after the initial dose, but patients should not exceed 200 mg in a 24-hour period.
• Patients with severe renal or hepatic impairment should start with the lower 50 mg dose.
• Ubrelvy works by blocking calcitonin gene-related peptide (CGRP) receptors, which play a key role in migraine pain signaling.
• The medication should be taken with or without food, though high-fat meals may delay its effectiveness.
• Patients should be aware that common side effects include nausea, tiredness, and dry mouth.
• Unlike triptans, Ubrelvy doesn't cause vasoconstriction, making it suitable for patients with cardiovascular risk factors who cannot take triptans.
• However, patients should inform their healthcare provider about all medications they take, as certain drugs (particularly strong CYP3A4 inhibitors like ketoconazole or clarithromycin) can interact with Ubrelvy and require dosage adjustments, as suggested by the guideline 1.

From the FDA Drug Label

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food. If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg.

The recommended use and dosage of UBRELVY (Ubrogepant) for treating migraine attacks in adults is:

• 50 mg or 100 mg taken orally with or without food
• A second dose may be taken at least 2 hours after the initial dose if needed
• The maximum dose in a 24-hour period is 200 mg 2

From the Research

Recommended Use and Dosage of UBRELVY (Ubrogepant)

• UBRELVY (Ubrogepant) is an orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adults 3.
• The recommended dosage of UBRELVY is 50- or 100-mg tablets, with a maximum dose of 200 mg within 48 hours 3.
• UBRELVY can be effective in alleviating migraine-associated symptoms such as nausea, photophobia, and sound sensitivity, in addition to minimizing pain 3.

Efficacy of UBRELVY

• Clinical trials have demonstrated the effectiveness and safety of UBRELVY in acute migraine attacks, with a significant percentage of participants achieving freedom from pain and absence of the most bothersome migraine-associated symptom at 2 hours after taking the medication 4, 5.
• UBRELVY has been shown to be effective in participants with a history of migraine with or without aura, regardless of their historical experience with triptans 6.

Safety and Tolerability

• UBRELVY has been found to have a favorable safety profile, with the most common adverse events being nausea, somnolence, and dry mouth 4, 5.
• UBRELVY is not effective as a preventive migraine therapy and should not be taken by patients with certain conditions, such as pregnancy or end-stage renal disease 3, 7.